Celyad Oncology SA
13 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer (NCT04991948) | Celyad Oncology SA | 2021-11-22 |
| Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma (NCT04613557) | Celyad Oncology SA | 2020-11-16 |
| Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02 (NCT04167696) | Celyad Oncology SA | 2019-11-25 |
| EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2 (NCT03612739) | Celyad Oncology SA | 2018-12-01 |
| Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer (NCT03370198) | Celyad Oncology SA | 2017-10-11 |
Track Celyad Oncology SA automatically
Every clearance here is in the API, with alerts when new ones post.